TScan Therapeutics (TCRX) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Barclays Maintains TScan Therapeutics(TCRX.US) With Buy Rating, Maintains Target Price $14
Moomoo NewsJan 16 05:35 ET · Ratings
Barclays Sticks to Its Buy Rating for TScan Therapeutics (TCRX)
TipRanksJan 16 05:18 ET · Ratings
Here's Why TScan Therapeutics (TCRX) Is Poised for a Turnaround After Losing -5.63% in 4 Weeks
Zacks Jan 10 08:50 ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session
BenzingaDec 26, 2024 16:05 ET
TScan Shares Jump 23% on Securities Purchase Agreement
WSJDec 26, 2024 09:13 ET
Sector Update: Health Care Stocks Steady Premarket Thursday
MT NewswiresDec 26, 2024 09:09 ET

Comments

Trytosaveabit

Dec 26, 2024 06:02

News

$TScan Therapeutics (TCRX.US)$ Press Release: TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium
Dow Jones· 1 min ago

1

Trytosaveabit

Dec 9, 2024 16:55

Watching

$TScan Therapeutics (TCRX.US)$ TScan Therapeutics To Present Updated Results From Ongoing ALLOHA Phase 1 Trial Of TSC-100 And TSC-101 At ASH Meeting
Benzinga· 1 min ago
TSC-100 and TSC-101 are designed to treat residual disease and prevent relapse in patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT) with reduced intensity conditioning.
The company said it is high...

MARKET-TEST-DUMMY

Dec 7, 2024 05:06

👁

$TScan Therapeutics (TCRX.US)$

Jaguar8

Nov 5, 2024 08:16

NEWS

$TScan Therapeutics (TCRX.US)$
TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition

Jaguar8

Oct 4, 2024 10:40

NEWS

$TScan Therapeutics (TCRX.US)$
TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company developing T cell receptor (TCR)-engineered T cell therapies for cancer treatment, announced the acceptance of three abstracts for poster presentationat the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting. The event will be held from November 6-10 in Houst...

TCRX TScan Therapeutics

Trade Overview

Capital Trend

News

Comments

Trending Stocks